ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy. - Liu S; Chen H; Gagea M; Federico L; Zhang F; Gomez J; Do KA; Symmans WF; Hortobagyi GN; Mills GB; Gonzalez-Angulo AM; Tripathy D (Cancer letters, 2025)